ONFI (clobazam)
ORAL ADMINISTRATION
Indications for Prior Authorization:
- Indiated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older
Patients must meet the following criteria for the indication(s) above:
- Prescribed by or in collaboration with a neurologist, AND
- 2 years of age or older, AND
- Diagnosis of Lennox-Gastaut syndrome, AND
- Currently receiving treatment with at least one other antiepileptic medication
Dosing:
- Dose patients according to body weight. Individualize dosing within each body weight group, based on clinical efficacy and tolerability.
| Less than or equal to 30 kg Body Weight | Greater than 30 kg Body weight | |
|---|---|---|
| Starting Dose | 5 mg | 10 mg |
| Starting Day 7 | 10 mg | 20 mg |
| Starting Day 14 | 20 mg | 40 mg |
- Administer tablets whole, broken in half along the score, or crushed and mixed in applesauce.
- To discontinue, taper by decreasing the total daily dose by 5-10 mg/day on a weekly basis until discontinued.
Approval:
- 1 year
Last review date: June 12, 2017